Berberine
Berberine
Berberine
Berberine
Berberine
Berberine
Berberine
Berberine
Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine
  • Load image into Gallery viewer, Berberine

Berberine

Regular price
$ 28.49
Sale price
$ 28.49
Regular price
Sold out
Unit price
per 
Free shipping at $100
  • The Basics
  • The Science

Berberine is an alkaloid found in many plants, but most notably in goldenseal (Hydrastis canadensis), barberry (Berberis vulgaris), Oregon grape (Berberis aquifolium), and goldthread (Coptis chinensis). These plants have a long history of use in supporting health. Berberine can be produced from various plant parts (e.g., seed, bark, root, etc.). Enzymedica’s Berberine is a sustainable product produced from the seeds of barberry (Berberis vulgaris).

Benefits:

  • Promotes a healthy microbiome
  • Balances intestinal function
  • Supports cardiovascular health
  • Helps maintain healthy blood sugar balance

 

Why Enzymedica?

  • Sustainable and preferred source of berberine from the seeds of barberry (Berberis vulgares).
  • Enteric-coated to prevent self-aggregation and formation berberine crystals that reduce absorption.

Enzymedica’s Berberine is provided in a targeted delivery capsule to prevent the breakdown of the capsule and subsequent release of berberine in the stomach. This type of capsule is recommended for berberine as in an acidic environment berberine will bind with other berberine molecules to form insoluble complexes that do not get absorbed. Prevention of the formation of these complex are thought to possibly double the absorption of berberine

Berberine has been extensively studied in clinical trials for positively influencing normal blood sugar, lipids, and hypertension. Recently, the Journal of Ethnopharmacology published a detailed review of the 27 clinical studies with berberine in these disorders that provided clear answer questions on its safety and efficacy.1

Berberine has also been examined as a weight loss aid in two double-blind clinical trials. In one study, 37 men and women with metabolic syndrome were given 300 mg of berberine three times per day for three months. The body mass index (BMI) levels dropped from 31.5 to 27.4.2 In another study, 500 mg of berberine three times per day caused an average of 5 pounds of weight loss over a 12-week period.3

Recommended adult dose/ Interactions

One 500 mg capsule before meals with a glass of water two to three times daily.

Berberine and berberine-containing plants are not recommended for use during pregnancy.

Berberine may interfere with the absorption of tetracycline and related antibiotics. Berberine produces significant inhibition of CYP3A enzymes in humans. Because most drugs are metabolized by these enzymes, berberine may decrease the clearance of many medications thereby potentiating their effect.

Berberine-containing plants may enhance the effects of oral hypoglycemic drugs through its multitude of anti-diabetic effects. People on oral hypoglycemic drugs should monitor blood glucose levels if taking berberine. Adjustment of drug dosage may be required.

1. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81.

2. Yang, J., Yin, J., Gao, H., Xu, L., Wang, Y., and Li, M. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid. Based Complement. Altern. Med. 2012; 2012: 363845.

3. Perez-Rubio, K.G., Gonzalez-Ortiz, M., Martinez-Abundis, E., Robles-Cervantes, J.A., and Espinel-Bermudez, M.C. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2013; 11: 366–369.